Evidence map›Paper›PMID 30764648›Full record

Trial reportThe American journal of psychiatry2019

Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Boadie W Dunlop, Devon LoParo, Becky Kinkead, Tanja Mletzko-Crowe, Steven P Cole, Charles B Nemeroff, Helen S Mayberg, W Edward Craighead

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Teaching residents about cognitive behavioural therapy.Canadian family physician Medecin de famille canadien · 2025
    Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Devon LoParoDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Becky KinkeadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Tanja Mletzko-CroweDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Steven P ColeDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Charles B NemeroffDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Helen S MaybergDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
W Edward CraigheadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).
Icahn School of Medicine at Mount Sinai · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 1985 to 2007
$21.3M
Special Scientific Procedures: Statistical Modeling CoreP50MH077083 · NIMH · EMORY UNIVERSITY · PI KUTNER, MICHAEL HENRY · 2006 to 2010
$9.3M
Predictors of Treatment Response Relapse and Recurrence in Major DepressionR01MH080880 · NIMH · EMORY UNIVERSITY · PI CRAIGHEAD, W. EDWARD · 2008 to 2012
$6.6M
Neural Correlates of Loss Aversion in Major DepressionK23MH086690 · NIMH · EMORY UNIVERSITY · PI DUNLOP, BOADIE W · 2009 to 2011
$521k
NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NIMH NIH HHS K23 MH086690NIMH NIH HHS P50 MH077083NIMH NIH HHS R01 MH080880
6 · The paper itself

Abstract

objectiveAdults with major depressive disorder frequently do not achieve remission with an initial treatment. Addition of psychotherapy for patients who do not achieve remission with antidepressant medication alone can target residual symptoms and protect against recurrence, but the utility of adding antidepressant medication after nonremission with cognitive-behavioral therapy (CBT) has received little study. The authors aimed to evaluate the acute and long-term outcomes resulting from both sequences of combination treatments.

methodsPreviously untreated adults with major depression who were randomly assigned to receive escitalopram, duloxetine, or CBT monotherapy and completed 12 weeks of treatment without achieving remission entered an additional 12 weeks of combination treatment. For patients who did not achieve remission with CBT, escitalopram was added (CBT plus medication group) to their treatment, and for those who did not achieve remission with an antidepressant, CBT was added (medication plus CBT group) to their treatment. Patients who responded to the combination treatment entered an 18-month follow-up phase to assess risk of recurrence.

resultsA total of 112 patients who did not achieve remission with a monotherapy entered combination treatment (41 who responded to monotherapy but did not achieve remission and 71 who did not respond to monotherapy). Overall, remission rates after subsequent combination therapy were significantly higher among patients who responded to monotherapy but did not achieve remission (61%) than among patients who did not respond to monotherapy (41%). Among patients who responded to monotherapy but did not achieve remission, the remission rate in the CBT plus medication group (89%) was higher than in the medication plus CBT group (53%). However, among patients whose depression did not respond to monotherapy, rates of response and remission were similar between the treatment arms. Higher levels of anxiety, both prior to monotherapy and prior to beginning combination treatment, predicted poorer outcomes for both treatment groups.

conclusionsThe order in which CBT and antidepressant medication were sequentially combined did not appear to affect outcomes. Addition of an antidepressant is an effective approach to treating residual symptoms for patients who do not achieve remission with CBT, as is adding CBT after antidepressant monotherapy. Patients who do not respond to one treatment modality warrant consideration for addition of the alternative modality.

Indexed as

AdultAntidepressive AgentsCitalopramCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, Treatment-ResistantDuloxetine HydrochlorideFemaleHumansMajor Depressive DisorderMaleTreatment FailureAntidepressive AgentsCitalopramDuloxetine HydrochlorideAntidepressive AgentAnxietyDepressionDuloxetineEscitalopramPsychotherapyRelapse

Identifiers

PMID30764648
PMCPMC6557125
OpenAlexW2911611400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.